Compugen医疗 CGEN 深 沪
等待开盘 08-27 09:30:00 美东时间
2.835
-0.035
-1.22%
华盛通- 最 高2.935
- 今 开2.83
- 成交量 49.50万股
- 最 低 2.80
- 昨 收 2.87
- 总市值 2.69亿
- 52周最高 3.235
- 市盈率 静 7.53
- 换手率 0.52%
- 52周最低 1.295
- 委 比 -43.26%
- 总股本 9472.79万
- 历史最高 19.90
- 量 比 1.12
- 振 幅 4.70%
- 历史最低 0.51
- 每 手 1
- 风险率 0.45%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Compugen Q2 EPS $(0.07), Inline, Sales $2.602M Beat $1.606M Estimate
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 12.5 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $2.602 million which beat the analyst consensus est...
08-03 19:01
Compugen Reports Second Quarter 2026 Results
COM701 MAIA-ovarian trial progressing as planned with median progression-free survival data from the interim analysis expected by Q1 2027 Trial-in-progress poster on MAIA-ovarian presented a...
08-03 19:00
Compugen To Present Trial-In-Progress Poster On MAIA-Ovarian Phase 1 Study Of COM701, Anti-PVRIG Antibody, At ESMO Gynaecological Cancers Congress 2026
Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a trial-in-progress poster on the MAIA-ovarian Phase 1 study of COM701, a potential first-in-c...
06-11 19:14
Compugen Q1 2026 Earnings Call: Complete Transcript
On Monday, Compugen (NASDAQ:CGEN) discussed first-quarter financial results dur...
06-01 21:04
美股大行评级 | 英伟达绩后获11家大行集体上调目标价；劳氏、ELF、Intuit、VF等惨遭多家大行下调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx药业"超配"评级，目标价从84美元升至96美元；Ascendiant Capital：维持Liqtech国际"买入"评级，目标价从4.3美元升至4.4美元
05-22 10:18
Leerink Partners Maintains Outperform on Compugen, Lowers Price Target to $5
Leerink Partners maintains Compugen (NASDAQ:CGEN) with a Outperform and lowers the price target from $13 to $5.
05-21 22:38
Earnings Scheduled For May 18, 2026
Companies Reporting Before The Bell • Compugen (NASDAQ:CGEN) is likely to repor...
05-18 19:11
Compugen Q1 EPS $(0.08) Misses $(0.07) Estimate, Sales $2.176M Beat $2.095M Estimate
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 14.29 percent. This is unchanged from the same period last year. The company reported
05-18 19:01
Compugen Reports First Quarter 2026 Results
COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the U.S., Israel, and France; interim analysis on track by Q1 2027 Partner AstraZeneca is advancing rilvego...
05-18 19:00
Compugen Q1 2026 Earnings Preview
Compugen (CGEN) is scheduled to announce Q1 earnings results on Monday, May 18th, after market close. The consensus EPS Estimate is -$0.08 (flat Y/Y) and the consensus Revenue Estimate is $1.26M (-45....
05-18 05:35
